Wrap Text
TR-1: Standard form for notification of major holdings
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company”, or the “Group”)
28 July 2022
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00B8HX8Z88
Issuer Name
MEDICLINIC INTERNATIONAL PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of financial instruments
3. Details of person subject to the notification obligation
Name
JPMorgan Chase & Co.
City of registered office (if applicable)
Country of registered office (if applicable)
US
4. Details of the shareholder
Name City of registered office Country of registered office
J.P. Morgan Securities plc
5. Date on which the threshold was crossed or reached
26-Jul-2022
6. Date on which Issuer notified
28-Jul-2022
7. Total positions of person(s) subject to the notification
obligation
% of voting % of voting Total of both Total number of
rights attached rights through in % (8.A + voting rights
to shares (total financial 8.B) held in issuer
of 8.A) instruments
(total of 8.B 1 +
8.B 2)
Resulting 0.949276 6.028796 6.978072 51445397
situation on the
date on which
threshold was
crossed or
reached
Position of 0.853682 5.153770 6.007452
previous
notification (if
applicable)
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of Number of Number of indirect % of direct % of indirect voting
shares ISIN direct voting voting rights voting rights rights (DTR5.2.1)
code(if possible) rights (DTR5.1) (DTR5.2.1) (DTR5.1)
GB00B8HX8Z88 6998477 0.949276
Sub Total 8.A 6998477 0.949276%
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Type of financial Expiration Exercise/conversion Number of voting rights that % of
instrument date period may be acquired if the voting
instrument is rights
exercised/converted
Sub Total 8.B1
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
Type of Expiration date Exercise/conversion Physical or Number of % of voting
financial period cash voting rights rights
instrument settlement
Cash- 23/11/2022 23/11/2022 Cash 24478246 3.320238
settled
Equity
Swap
Cash- 04/01/2023 04/01/2023 Cash 137352 0.018630
settled
Equity
Swap
Cash- 01/02/2023 01/02/2023 Cash 16152 0.002191
settled
Equity
Swap
Cash- 22/02/2023 22/02/2023 Cash 41629 0.005647
settled
Equity
Swap
Cash- 17/03/2023 17/03/2023 Cash 12542 0.001701
settled
Equity
Swap
Cash- 30/05/2023 30/05/2023 Cash 99 0.000013
settled
Equity
Swap
Cash- 02/06/2023 02/06/2023 Cash 12389778 1.680554
settled
Equity
Swap
Cash- 04/07/2023 04/07/2023 Cash 6583319 0.892964
settled
Equity
Swap
Cash- 12/07/2023 12/07/2023 Cash 25586 0.003470
settled
Equity
Swap
Cash- 26/07/2023 26/07/2023 Cash 177975 0.024141
settled
Equity
Swap
Cash- 09/08/2023 09/08/2023 Cash 759 0.000103
settled
Equity
Swap
Cash- 16/08/2023 16/08/2023 Cash 10300 0.001397
settled
Equity
Swap
Cash- 21/08/2023 21/08/2023 Cash 515 0.000070
settled
Equity
Swap
Cash- 22/08/2023 22/08/2023 Cash 598 0.000081
settled
Equity
Swap
Cash- 04/09/2023 04/09/2023 Cash 5619 0.000762
settled
Equity
Swap
Cash- 19/01/2024 19/01/2024 Cash 38927 0.005280
settled
Equity
Swap
Cash- 05/01/2027 05/01/2027 Cash 462150 0.062686
settled
Equity
Swap
Cash- 06/07/2027 06/07/2027 Cash 93 0.000013
settled
Equity
Swap
Cash- 09/07/2029 09/07/2029 Cash 65281 0.008855
settled
Equity
Swap
Sub Total 8.B2
44446920 6.028796%
9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held starting with the
ultimate controlling natural person or legal entities (please add
additional rows as necessary)
Ultimate Name of controlled % of voting % of voting rights Total of both if it
controlling person undertaking rights if it through financial equals or is higher
equals or is instruments if it than the notifiable
higher than equals or is higher threshold
the notifiable than the notifiable
threshold threshold
JPMorgan J.P. Morgan 6.028796 6.028796%
Chase & Co. Securities plc
JPMorgan JPMorgan
Chase & Co. Chase Bank,
National
Association
JPMorgan J.P. Morgan
Chase & Co. Equities South
Africa
Proprietary
Limited
JPMorgan J.P. Morgan
Chase & Co. SE
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
Chain of controlled undertakings:
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan Capital Holdings Limited (100%)
J.P. Morgan Securities plc (100%)
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan Capital Holdings Limited (100%)
J.P. Morgan Equities South Africa Proprietary Limited (100%)
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan SE (100%)
12. Date of Completion
28-Jul-2022
13. Place Of Completion
London
About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.
The Group’s core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum
of care in such a way that the Group will be regarded as the most respected and trusted provider of
healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of
its markets.
At 31 March 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health
facilities, 20 day case clinics and 22 outpatient clinics. The Swiss operations included 17 hospitals and
four day case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals
(three of which in Namibia), five subacute hospitals, two mental health facilities and 14 day case clinics
(four of which operated by Intercare) across South Africa, and around 8 650 inpatient beds; and the
Middle East operated seven hospitals, two day case clinics and 22 outpatient clinics with around 1 000
inpatient beds in the UAE. In addition, under management contract the Middle East will open a 200-bed
hospital in the Kingdom of Saudi Arabia in 2023.
The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United Kingdom, with
secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the United Kingdom and listed on the LSE
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930
Investor queries
James Arnold, Head of Investor Relations, Mediclinic International plc
+44 (0)20 3786 8181
ir@mediclinic.com
Media queries
FTI Consulting
Ben Atwell/Ciara Martin - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, UK
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 28-07-2022 03:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
